Workflow
CHALKIS(000972)
icon
Search documents
中基健康(000972) - 2023 Q1 - 季度财报
2023-04-27 16:00
Financial Performance - The company's revenue for Q1 2023 reached ¥149,986,679.55, a significant increase of 502.91% compared to ¥24,877,144.60 in the same period last year[4] - Net profit attributable to shareholders was ¥16,882,477.46, a turnaround from a loss of ¥4,986,755.44 in the previous year[4] - The total operating revenue for Q1 2023 was CNY 149,986,679.55, a significant increase from CNY 24,893,658.36 in the same period last year, representing a growth of approximately 502.5%[18] - The operating income for Q1 2023 was CNY 149,986,679.55, up from CNY 24,877,144.60 in the previous year, reflecting a growth of approximately 502.5%[18] - The company reported a net loss of CNY 1,767,177,601.07, slightly improved from a loss of CNY 1,784,060,078.53 in the previous period[16] - The company's net profit for Q1 2023 reached CNY 16,854,769.66, a significant recovery from a net loss of CNY 4,995,605.10 in the same period last year, marking a turnaround of over 436%[19] - Operating profit for the quarter was CNY 16,965,309.28, compared to an operating loss of CNY 5,017,714.54 in Q1 2022, indicating a strong operational performance improvement[19] - The company reported basic and diluted earnings per share of CNY 0.0219, recovering from a loss per share of CNY -0.0065 in Q1 2022[19] Cash Flow and Liquidity - The net cash flow from operating activities increased by 47.52% to ¥63,401,042.48 from ¥42,976,551.37 year-on-year[4] - Cash flow from operating activities generated a net inflow of CNY 63,401,042.48, up from CNY 42,976,551.37 in the previous year, reflecting a growth of approximately 47%[20] - The cash and cash equivalents at the end of Q1 2023 were CNY 249,557,422.61, an increase from CNY 207,471,741.60 at the beginning of the year, showing a growth of about 20.3%[14] - The cash and cash equivalents at the end of the period totaled CNY 249,557,422.61, compared to CNY 63,204,247.88 at the end of Q1 2022, showing a significant increase of approximately 295%[21] Assets and Liabilities - Total assets decreased by 9.40% to ¥747,759,865.77 from ¥825,364,850.66 at the end of the previous year[4] - Total assets as of March 31, 2023, were CNY 747,759,865.77, down from CNY 825,364,850.66 at the beginning of the year, reflecting a decrease of approximately 9.4%[16] - Total liabilities decreased to CNY 630,484,002.22 from CNY 724,943,756.77, a reduction of about 12.9%[16] - The total equity attributable to shareholders of the parent company increased to CNY 112,196,664.15 from CNY 95,314,186.69, representing a growth of approximately 17.7%[16] Operational Efficiency - Accounts receivable decreased by 64.70% to ¥31,245,338.31, reflecting effective collection of previous sales[8] - Accounts receivable decreased to CNY 31,245,338.31 from CNY 88,520,062.41, a reduction of approximately 64.7%[14] - Inventory decreased by 42.03% to ¥125,654,535.42 due to seasonal production and sales[8] - Inventory levels decreased to CNY 125,654,535.42 from CNY 216,762,597.82, indicating a decline of about 42.1%[15] Expenses and Investments - The total operating costs for Q1 2023 amounted to CNY 134,587,988.45, compared to CNY 30,042,866.00 in Q1 2022, indicating an increase of about 348.5%[18] - The company incurred total expenses of CNY 127,165,385.99 in operating activities, compared to CNY 23,662,896.48 in the same period last year, indicating a rise in operational costs[20] - The company made a long-term equity investment of ¥4,000,000.00 during the quarter, indicating strategic expansion efforts[9] - The company reported a significant increase in sales expenses by 874.70% to ¥1,370,036.82, driven by higher sales volume[9] Government Support and R&D - The company received government subsidies amounting to ¥100,723.82, contributing to other income[7] - The company has not reported any research and development expenses for the quarter, indicating a potential area for future investment[19] - The company has not disclosed any new product developments or market expansion strategies in this report, suggesting a focus on consolidating current operations[19]
中基健康:中兴财光华会计师事务所(特殊普通合伙)关于对中基健康产业股份有限公司深圳证券交易所重组问询函的回复
2023-04-26 16:02
关于对中基健康产业股份有限公司 深圳证券交易所重组问询函的回复 关于对中基健康产业股份有限公司 报告书显示,新疆新粮艳阳天番茄股份有限公司(以下简称"新粮艳阳天"或 "标的公司")的主营业务为番茄制品的生产和销售,主要产品为大桶番茄酱和小包 装 番茄制品。此外,报告期内新粮艳阳天还从事番茄制品的贸易业务和代理服务。 2022 年,新粮艳阳天自产番茄制品业务收入 3,940.65 万元,占主营业务收入的 27.76%, 番茄制品贸易业务收入 10,205.54 万元,占主营业务收入的 71.89%,贸易业务收入中以 总额法确认收入占比 93.32%,以净额法确认收入占比 6.68%。 请你公司: (1)按业务模式,分季度说明新粮艳阳天报告期内主要业务的开展情况,包括 但不限于实现的营业收入、营业成本、毛利率等主要财务指标,并详细说明相关贸易 业务和代理服务的盈利模式; (2) 说明报告期内新粮艳阳天采用总额法和净额法确认收入的贸易业务内容、 金额,采用不同收入确认方法的依据及合理性; (3)说明标的公司贸易业务的销售路径,物流与资金流的匹配情况,相关客户 采购后的销售或使用情况、退换货情况,是否存在相关产品在各 ...
中基健康(000972) - 2022 Q4 - 年度财报
2023-02-24 16:00
Financial Performance - The company's operating revenue for 2022 was ¥589,285,550.34, representing a 237.79% increase compared to ¥174,451,612.86 in 2021[20] - The net profit attributable to shareholders was ¥26,085,146.48, a significant recovery from a loss of ¥106,814,799.25 in the previous year[20] - The net cash flow from operating activities was ¥197,747,426.27, improving from a negative cash flow of ¥188,674,681.95 in 2021[20] - Basic earnings per share for 2022 were ¥0.03, compared to a loss of ¥0.14 per share in 2021[20] - The total assets at the end of 2022 were ¥825,364,850.66, an increase of 22.09% from ¥676,041,526.27 at the end of 2021[20] - The net assets attributable to shareholders increased by 37.68% to ¥95,314,186.69 from ¥69,229,040.21 in 2021[20] - The company's weighted average return on equity was 31.71%, a significant increase of 118.81 percentage points from -87.10% in the previous year[20] - The company achieved total operating revenue of CNY 435,115,680.77 in Q4 2022, with a total annual revenue of CNY 58,928.56 million[24] - The net profit attributable to shareholders of the listed company in Q4 2022 was CNY 50,644,711.33, marking a significant recovery from previous quarters[24] - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2022, representing a year-over-year increase of 15%[79] Operational Strategy - The company plans not to distribute cash dividends or issue bonus shares for the year[6] - The company plans to enhance its production capacity and reduce costs by increasing raw material area and improving equipment utilization rates[30] - The company is focusing on developing high-value-added products such as lycopene health supplements and is initiating the production and sales of small jar products[30] - The company aims to integrate asset management and capital operations to enhance its operational efficiency and profitability[31] - The company plans to produce 100,000 tons of large-pack tomato sauce and 400,000 bottles of lycopene in 2023[59] - The company aims to enhance production capacity for large-pack tomato sauce to achieve quality improvement and cost reduction[60] - The company will focus on developing fast-moving consumer goods and health products to strengthen its market position[60] Market and Product Development - The manufacturing sector contributed ¥576,599,200.85, accounting for 97.85% of total revenue, with a year-on-year growth of 247.86%[37] - The sales volume of large-pack tomato sauce increased by 161.52% to 78,606.98 tons in 2022, while production volume rose by 42.34% to 82,958.11 tons[39] - The gross profit margin for large-pack tomato sauce improved to 16.53%, up by 14.16% from the previous year[38] - The company is focusing on developing high-value-added tomato lycopene health products as part of its strategy to extend the industrial chain[36] - New product launches in 2022 included two health supplements, which contributed to a 10% increase in sales volume[79] - Market expansion efforts have led to the establishment of 50 new distribution channels across five provinces in 2022[79] Financial Management - The total operating cost for the manufacturing sector was ¥427,719,466.46, reflecting a year-on-year increase of 172.21%[38] - Sales expenses increased significantly by 5,852.57% to ¥5,705,666.49 in 2022 from ¥95,852.14 in 2021[46] - Operating cash inflow totaled ¥763,070,620.01, a 347.31% increase compared to ¥170,591,574.35 in 2021[47] - The company's cash and cash equivalents increased by ¥155,163,306.25, compared to a decrease of ¥16,593,723.22 in 2021, representing a 1035.07% change[48] - The proportion of cash and cash equivalents to total assets rose from 3.03% at the beginning of 2022 to 25.14% by year-end, an increase of 22.11%[49] Governance and Compliance - The total remuneration for 13 directors, supervisors, and senior management was CNY 2.3378 million (including tax) as of December 31, 2022[87] - The company held multiple board meetings throughout 2022, including discussions on the 2021 annual report and financial decisions[89] - The company is actively involved in governance and compliance, as evidenced by the detailed reporting of board activities and decisions[89] - The company has a clear strategy for future growth, including potential mergers and acquisitions as part of its expansion plans[89] - The company is focusing on enhancing its corporate governance structure to ensure compliance with relevant laws and regulations[67] Legal and Regulatory Issues - The company is involved in a legal case where it has been added as a defendant due to a previous subsidiary's bankruptcy proceedings[123] - The company has committed to pay a total of RMB 19.8 million to the court in three installments by December 10, 2022[126] - The company is involved in a legal dispute with Xinjiang Jinsheng Hu Yang Asset Management Co., which has resulted in a court order to freeze dividends amounting to RMB 12.4 million related to its 100% equity in Hongse Tomato[125] - The company has faced multiple legal challenges, including an appeal to the Xinjiang High Court, which upheld the lower court's decision[124] Employee and Management Structure - The total number of employees at the end of the reporting period was 221, with 40 in the parent company and 181 in major subsidiaries[97] - The professional composition of employees includes 123 production personnel, 19 sales personnel, 1 technical personnel, 19 financial personnel, and 59 administrative personnel[97] - The company has established a performance evaluation and reward system based on job positions, ensuring transparency and compliance with legal regulations[99] - The company has implemented a training mechanism that combines internal and external training to enhance employee capabilities and quality[100] Environmental and Social Responsibility - The company has implemented measures to enhance energy efficiency and wastewater treatment capabilities, contributing to environmental protection[111] - The company is committed to social responsibility, focusing on poverty alleviation and regional economic growth through agricultural development[111]
中基健康(000972) - 2022 Q3 - 季度财报
2022-10-26 16:00
Financial Performance - The company's operating revenue for Q3 2022 reached ¥53,088,896.01, representing a significant increase of 1,153.93% compared to the same period last year[4] - Total operating revenue for Q3 2022 reached ¥154,169,869.57, a significant increase from ¥7,359,465.17 in the same period last year, representing a growth of approximately 1,973%[20] - The net profit attributable to shareholders was ¥2,608,309.73, while the net profit after deducting non-recurring gains and losses was ¥2,075,452.02, indicating a recovery from previous losses[4] - The net profit for Q3 2022 was -¥24,557,362.28, an improvement from -¥54,876,089.09 in Q3 2021, reflecting a reduction in losses of approximately 55%[22] - Cash received from sales and services amounted to ¥348,581,823.20, reflecting a 2,209.55% increase year-on-year[8] - Cash received from sales of goods and services in Q3 2022 was ¥348,581,823.20, compared to ¥15,093,064.71 in Q3 2021, showing a growth of approximately 2,200%[22] Assets and Liabilities - Total assets increased by 46.05% year-on-year, reaching ¥987,388,973.30, while equity attributable to shareholders decreased by 35.48% to ¥44,669,475.36[4] - Total liabilities as of the end of Q3 2022 amounted to ¥937,609,660.00, up from ¥601,705,050.46 at the end of the previous year, marking an increase of approximately 55.7%[21] - The total equity attributable to shareholders of the parent company was ¥44,669,475.36, down from ¥69,229,040.21 year-over-year, indicating a decline of about 35.4%[21] - Current assets amounted to 702,305,556.55 yuan, up from 358,575,010.18 yuan at the start of the year[17] - The company has a total of 285,083,416.75 yuan in non-current assets, down from 317,466,516.09 yuan[17] Cash Flow - The company reported a net cash flow from operating activities of ¥86,836,466.34, a decline of 133.29% year-to-date[4] - The net cash flow from operating activities for Q3 2022 was ¥86,836,466.34, a turnaround from -¥260,820,543.21 in the same quarter last year[22] - The net cash flow from investment activities was 1,272,359.83, compared to a net outflow of 1,226,995.12 in the previous period[23] - The total cash inflow from financing activities was 0.00, while the cash outflow was 19,355,129.50, resulting in a net cash flow of -19,355,129.50[23] - The cash and cash equivalents at the end of the period increased to 89,271,187.09, up from 50,547,571.13 in the previous period[23] - The cash flow from operating activities was not detailed in the provided data, indicating a focus on investment and financing activities[23] Operational Efficiency and Future Plans - The company plans to continue expanding its production capabilities and improving operational efficiency to enhance profitability in the upcoming quarters[4] - The company is in the process of a major asset restructuring, with ongoing audits and evaluations[14] - The company will issue progress announcements on the asset restructuring every 30 days until the shareholder meeting notification is sent out[14] Shareholder Information - Total number of common shareholders at the end of the reporting period is 27,241[10] - The largest shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., holds 16.18% of shares, totaling 124,769,223 shares, with 59,621,900 shares pledged[10] Research and Development - Research and development expenses were reported at ¥62,190.89, indicating a focus on innovation despite previous financial challenges[8] - Research and development expenses for Q3 2022 were ¥62,190.89, compared to no expenses in the same period last year, indicating a commitment to innovation[21] Other Financial Metrics - The gross profit margin improved, with operating costs rising to ¥137,996,368.64, a 1,652.71% increase compared to the previous year, driven by higher sales volume[7] - The company recorded a significant increase in government subsidies, totaling ¥587,639.63 for the current period, up from previous amounts[6] - The company has seen a 220% increase in cash received from tax refunds, amounting to ¥13,913,435.65, due to favorable national policies[8] - The company reported a credit impairment loss of -¥16,939,866.23 in Q3 2022, worsening from -¥7,435,512.20 in Q3 2021, reflecting increased credit risk[21] Audit and Reporting - The company did not undergo an audit for the third quarter report[24] - The company’s board of directors issued the report on October 26, 2022, reflecting timely financial disclosures[25]
中基健康(000972) - 2022 Q2 - 季度财报
2022-08-23 16:00
Financial Performance - The company's operating revenue for the first half of 2022 was ¥101,080,973.56, representing a significant increase of 3,133.90% compared to ¥3,125,663.72 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was a loss of ¥27,167,874.58, an improvement of 41.32% from a loss of ¥46,300,485.73 in the previous year[21]. - The net cash flow from operating activities was ¥136,519,260.04, a substantial recovery from a negative cash flow of ¥18,531,697.98 in the same period last year[21]. - The basic earnings per share improved to -¥0.04 from -¥0.06, reflecting a 33.33% increase[21]. - The company reported a net loss of CNY 1,837,313,099.59 in retained earnings as of June 30, 2022, compared to a loss of CNY 1,810,145,225.01 at the beginning of the year[106]. - The total comprehensive income for the first half of 2022 was a loss of CNY 27,162,956.54, compared to a loss of CNY 46,321,199.04 in the same period of 2021[114]. Assets and Liabilities - The total assets at the end of the reporting period were ¥664,541,768.43, a decrease of 1.70% from ¥676,041,526.27 at the end of the previous year[21]. - The total liabilities increased to CNY 617,368,049.39 as of June 30, 2022, compared to CNY 601,705,050.46 at the start of the year, representing an increase of approximately 2.8%[106]. - The company's total equity decreased to CNY 47,173,719.04 from CNY 74,336,475.81 at the beginning of the year, a decline of about 36.5%[106]. - Cash and cash equivalents increased to ¥138,524,504.18, representing 20.85% of total assets, up from 3.03% last year, a significant increase of 17.82%[38]. - Accounts receivable decreased to ¥89,343,083.66, accounting for 13.44% of total assets, down from 20.06% last year, a decline of 6.62%[38]. - Inventory decreased to ¥89,797,149.50, making up 13.51% of total assets, down from 23.79% last year, a reduction of 10.28%[38]. Operational Highlights - The company has fully restored its tomato production and is optimizing the product structure to focus on high-value tomato products[29]. - The manufacturing sector accounted for 99.51% of total revenue, with large bucket tomato sauce contributing ¥92,225,255.00, representing 91.24% of total revenue[35]. - Management expenses decreased by 61.83% to ¥13,422,736.02 due to normal factory operations and reduced costs[33]. - The company plans to expand its production of high-value tomato products, including tomato lycopene health products and small-pack tomato sauce[29]. - The company has established a stable and low-cost raw material supply chain, increasing the planted area for tomato raw materials to ensure supply for the second half of the year[30]. Risk Management - The company faces risks from adverse weather conditions affecting tomato yield and quality, as well as high market concentration and low product differentiation in the tomato paste sector[49]. - The company emphasizes the importance of risk awareness regarding forward-looking statements made in the report[5]. Corporate Governance and Compliance - The company has not been subject to any administrative penalties due to environmental issues during the reporting period[58]. - There were no stock incentive plans, employee stock ownership plans, or other employee incentive measures implemented during the reporting period[55]. - The half-year financial report has not been audited[64]. - The company has not engaged in any related party transactions during the reporting period[72]. Future Outlook - The company plans to fully restore tomato production, anticipating a favorable market for tomato paste due to rising prices and reduced competition from smaller firms[47]. - The company aims to enhance its capital operation efficiency and explore long-term incentive mechanisms for sustainable development[48]. - Future performance guidance suggests a cautious optimism, with expectations of gradual recovery in market conditions[131]. Shareholder Information - The total number of shares remains at 771,283,579, with no changes in the shareholding structure[89]. - The largest shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., holds 16.18% of shares, totaling 124,769,223 shares[91]. - The second largest shareholder, Xinjiang Guoheng Investment Development Group Co., holds 12.97% of shares, totaling 100,000,000 shares[91].
中基健康(000972) - 2022 Q1 - 季度财报
2022-07-08 16:00
Financial Performance - The company's operating revenue for Q1 2022 was ¥24,893,658.36, a 100.00% increase compared to the same period last year when there was no revenue[3] - The net profit attributable to shareholders was -¥4,986,755.44, an improvement from -¥19,979,751.27 in the previous year, indicating a 75.01% reduction in losses[3] - The net profit for the first quarter of 2022 was -4,995,605.10 CNY, compared to -19,988,180.25 CNY in the same period last year, showing a significant improvement[19] - The total comprehensive income for the first quarter was -4,995,605.10 CNY, compared to -19,988,180.25 CNY in the previous year, indicating a reduction in losses[20] - Basic and diluted earnings per share were both -0.0065 CNY, an improvement from -0.0259 CNY in the same quarter of the previous year[20] - The company reported operating profit of -5,017,714.54 CNY, an improvement from -19,992,428.02 CNY in the same period last year[19] Cash Flow and Liquidity - The net cash flow from operating activities was ¥42,976,551.37, a significant recovery from -¥25,390,802.51 in the same period last year[3] - Cash flow from operating activities generated a net inflow of 42,976,551.37 CNY, a turnaround from a net outflow of -25,390,802.51 CNY in the previous year[21] - Cash and cash equivalents at the end of the period totaled 63,204,247.88 CNY, up from 10,548,551.53 CNY at the end of the previous year[22] - The company's cash and cash equivalents rose by 208.05% to ¥63,204,247.88 due to increased sales and recovery of previous year receivables[7] Assets and Liabilities - Total assets increased by 3.45% to ¥699,343,986.21 compared to the end of the previous year[3] - Total assets as of March 31, 2022, were CNY 699,343,986.21, up from CNY 676,041,526.27 at the beginning of the year, reflecting an increase of 3.4%[16] - Total liabilities increased to CNY 630,002,798.51 from CNY 601,705,050.46, marking a rise of 4.7%[15] - The company's total equity decreased to CNY 69,341,187.70 from CNY 74,336,475.81, a decline of 6.7%[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,338[10] - The top three shareholders hold a combined 35.65% of the company's shares, indicating significant ownership concentration[10] Operating Costs and Expenses - Total operating costs for Q1 2022 amounted to CNY 30,042,866.00, an increase from CNY 20,017,428.02 year-on-year[18] - Financial expenses for Q1 2022 were CNY 3,982,040.04, compared to CNY 1,345,108.05 in the previous year, indicating a significant increase[18] - Research and development expenses were CNY 458.49, with no prior year comparison available[18] Receivables and Inventory - The accounts receivable increased by 132.04% to ¥9,177,723.68, reflecting higher sales activity[7] - Accounts receivable decreased to CNY 126,855,321.23 from CNY 135,604,961.65, a decline of 6.0%[13] - Inventory decreased to CNY 151,678,614.40 from CNY 160,812,447.35, a reduction of 5.8%[14] Government Subsidies - The company received government subsidies amounting to ¥89,218.29, contributing to its non-operating income[5] Investment Activities - The total cash outflow from investing activities was -18,960.00 CNY, compared to -732,049.14 CNY in the previous year, indicating reduced investment losses[22] - The company paid 270,000.00 CNY in financing activities, compared to 344,999.99 CNY in the previous year, reflecting a decrease in financing costs[22]
中基健康(000972) - 2021 Q4 - 年度财报
2022-07-08 16:00
Financial Performance - The company's operating revenue for 2021 was approximately ¥174.45 million, representing a 659.61% increase compared to ¥22.97 million in 2020[19]. - The net profit attributable to shareholders for 2021 was a loss of approximately ¥106.81 million, an improvement from a loss of ¥265.89 million in 2020[19]. - The net cash flow from operating activities for 2021 was a negative ¥188.67 million, compared to a negative ¥9.89 million in 2020[19]. - The total assets at the end of 2021 were approximately ¥676.04 million, a 16.06% increase from ¥582.51 million at the end of 2020[19]. - The net assets attributable to shareholders decreased by 60.68% to approximately ¥69.23 million at the end of 2021, down from ¥176.04 million at the end of 2020[19]. - The basic earnings per share for 2021 was -¥0.14, an improvement from -¥0.34 in 2020[19]. - The weighted average return on net assets for 2021 was -87.10%, slightly worse than -86.05% in 2020[19]. - The company achieved total operating revenue of CNY 174.45 million in 2021, a significant increase from CNY 22.97 million in 2020[20]. - The net profit attributable to shareholders was CNY -106.81 million in 2021, compared to CNY -10.68 million in 2020[29]. - The gross profit margin for the manufacturing sector was 2.38%, with total operating costs amounting to ¥155,157,837.74[39]. - The company reported a total revenue of 1.5 billion in 2021, representing a year-over-year growth of 15%[76]. - The company reported a total revenue of 10,000 million in 2021, with a significant increase of 1,700 million compared to the previous year[77]. - The company reported a net profit of -106,874,713.82 CNY for the year 2021, with a net profit attributable to shareholders of the parent company at -106,814,799.25 CNY[179]. Operational Activities - The company produced over 58,000 tons of bulk tomato sauce during the production period from August 8 to September 30, 2021, equivalent to 72,000 tons of standard sauce[31]. - The company sold 30,058.06 tons of bulk tomato sauce in 2021, with a production volume of 58,282.83 tons and an ending inventory of 28,224.78 tons[40]. - The company has resumed production of high-value tomato lycopene health products to optimize its product structure[34]. - The company has resumed production of large-packaged tomato sauce after a halt due to market conditions, ensuring the continuity of its main business[52]. - The company has fully restored its tomato industry production, with a focus on high-value tomato products and small-packaged tomato sauce, aiming to strengthen its "red industry" [65]. - The company plans to produce 80,000 tons of large-packaged tomato sauce and 200,000 bottles of lycopene in 2022[64]. Market and Strategic Initiatives - The company plans to enhance its market operations and cost management to improve the financial status of the tomato industry[29]. - The company is focusing on integrating and optimizing resources to reduce operational burdens through leasing arrangements[30]. - The company is exploring long-term incentive mechanisms and employee stock ownership to ensure sustainable development [65]. - The company aims to leverage capital market financing and restructuring effects to increase resilience and create new profit growth points [66]. - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products and technologies were not detailed in the report[79]. - The company has completed a strategic acquisition of a smaller competitor for 300 million, expected to enhance market share[76]. - Market expansion plans include entering three new international markets by the end of 2022[76]. Financial Position and Liabilities - The company's fixed assets decreased by 14.2% from ¥354,399,017.09 at the beginning of the year to ¥315,290,506.46 at the end of the year[55]. - The company's inventory increased to ¥160,812,447.35, representing 23.79% of total assets[55]. - The company has set aside over 24 million yuan to address the debt issue from the bankruptcy proceedings of its former subsidiary, with a repayment ratio of 10.14%[128]. - The company has a frozen bank account balance of RMB 9,377.65 and RMB 3,362.29 in two different accounts[134]. - The company was ordered to pay a total of RMB 124,628,370.62, which includes principal, appraisal fees, and court costs[134]. - A contingent liability of 123,970,926.36 CNY was recognized related to a legal dispute with Xinjiang Jinseng Hu Yang Asset Management Co., Ltd.[184]. Governance and Compliance - The company has established a complete independent governance structure, ensuring compliance with relevant laws and regulations [71]. - The company maintains independence from its controlling shareholders in business, personnel, assets, organization, and finance [72]. - The company has implemented a training mechanism for employees, focusing on leadership and general skills development[103]. - The company conducted a self-inspection of corporate governance in accordance with regulatory requirements[112]. - The company has retained its accounting firm for seven years, with an audit fee of 1.2 million yuan for the current period[125]. - The audit opinion issued was a qualified opinion with a significant uncertainty regarding the company's ability to continue as a going concern[177]. Human Resources - The total number of employees at the end of the reporting period is 149, with 28 in the parent company and 121 in major subsidiaries[101]. - The professional composition includes 83 production personnel, 20 financial personnel, and 22 administrative personnel, among others[101]. - The educational background of employees shows 2 with postgraduate degrees, 19 with bachelor's degrees, and 61 with associate degrees[101]. - The company has established a performance evaluation and incentive mechanism based on a transparent salary system[102]. Environmental and Social Responsibility - The company is not classified as a key pollutant discharge unit and has not faced any administrative penalties related to environmental issues during the reporting period[115]. - The company has implemented measures to reduce carbon emissions, including energy-saving initiatives and improvements in energy utilization and wastewater treatment capabilities[115]. - The company has a commitment to social responsibility, focusing on poverty alleviation and regional economic growth, contributing to local agricultural development and farmers' income[116].
中基健康(000972) - 2021 Q4 - 年度财报
2022-05-27 16:00
Financial Performance - The company's operating revenue for 2021 was approximately ¥174.45 million, representing a 659.61% increase compared to ¥22.97 million in 2020[19]. - The net profit attributable to shareholders for 2021 was a loss of approximately ¥100.52 million, an improvement from a loss of ¥265.89 million in 2020[19]. - The net cash flow from operating activities for 2021 was a negative ¥188.67 million, compared to a negative ¥9.89 million in 2020[19]. - The total assets at the end of 2021 were approximately ¥682.34 million, an increase of 17.14% from ¥582.51 million at the end of 2020[19]. - The net assets attributable to shareholders decreased by 57.10% to approximately ¥75.52 million at the end of 2021 from ¥176.04 million at the end of 2020[19]. - The basic earnings per share for 2021 was -¥0.13, an improvement from -¥0.34 in 2020[19]. - The weighted average return on net assets for 2021 was -79.92%, a decrease of 6.13 percentage points from -86.05% in 2020[19]. - The company reported a net profit of -100,580,101.65 CNY for the year 2021, with a net profit attributable to shareholders of -100,520,187.08 CNY[175]. - The net loss for 2021 was CNY 100,580,101.65, compared to a net loss of CNY 266,724,598.87 in 2020, showing an improvement of approximately 62.3%[200]. Revenue and Sales - The company achieved total operating revenue of CNY 174.45 million in 2021, a significant increase from CNY 22.97 million in 2020[20]. - The total revenue for 2021 reached ¥174,451,612.86, representing a significant increase of 659.61% compared to ¥22,966,067.61 in 2020[36]. - The manufacturing sector contributed ¥165,753,883.70, accounting for 95.01% of total revenue, while rental services generated ¥7,987,472.83, a decrease of 65.09% year-over-year[36]. - The major product, bulk tomato sauce, generated revenue of ¥158,933,143.77, which is 91.10% of total revenue[36]. - Total sales amount from the top five customers reached ¥173,488,896.02, accounting for 99.44% of the annual sales[47]. Production and Operations - The company produced over 58,000 tons of bulk tomato sauce during the production period from August 8 to September 30, 2021, equivalent to 72,000 tons of standard sauce[31]. - The company produced over 58,282.83 tons of bulk tomato sauce in 2021, with a sales volume of 30,058.06 tons[40]. - The company has resumed production of high-value tomato lycopene health products to optimize its product structure[34]. - The company operates under a "leading enterprise + base + farmers" model to ensure stable raw material procurement[34]. - The company has fully restored its tomato industry production, optimizing the product structure and resuming the production of high-value tomato lycopene health products and small-packaged tomato sauce[65]. Cash Flow and Assets - The company reported a net cash flow from operating activities of CNY 72.15 million in the fourth quarter, following a negative cash flow in the previous quarters[24]. - Operating cash inflow totaled ¥170,591,574.35, a significant increase of 509.16% year-on-year[51]. - Operating cash outflow reached ¥359,266,256.30, an increase of 848.10% compared to the previous year[51]. - The company's inventory increased to ¥160,812,447.35, representing 23.57% of total assets[55]. - Fixed assets decreased to ¥315,290,506.46, accounting for 46.21% of total assets, down 14.63%[55]. Future Plans and Strategies - The company plans to apply for the removal of the delisting risk warning after the 2021 annual report disclosure, but the approval remains uncertain[5]. - The company plans to produce 80,000 tons of large-pack tomato sauce and 200,000 bottles of lycopene in the upcoming year[64]. - The company aims to achieve profitability in 2022 after a period of losses[64]. - The company is focusing on integrating and optimizing resources to reduce operational burdens through leasing arrangements[30]. - The company plans to enhance its market-oriented operational mechanism and improve cost management to boost the profitability of its tomato industry[29]. Governance and Management - The total remuneration for directors, supervisors, and senior management was CNY 1.7465 million (including tax) for the year ended December 31, 2021[90]. - The company has established a complete independent governance structure, ensuring separation from its controlling shareholder in business, personnel, assets, organization, and finance[72]. - The company is focused on maintaining transparency in its remuneration practices and ensuring compliance with relevant regulations[90]. - The company held multiple board meetings during the reporting period, including the third and fourth meetings of the eighth board and several temporary meetings, with key resolutions passed regarding the 2020 annual report and financial statements[93]. Legal and Compliance Issues - The company reported a negative net profit for the year, leading to a "delisting risk warning" from the Shenzhen Stock Exchange due to revenues falling below 100 million yuan[124]. - The company has been ordered to pay a total of RMB 124,628,370.62, which includes principal, fees, and other costs related to a legal dispute[130]. - The company has frozen assets including RMB 123,970,926.36 in deposits and dividends from its subsidiary, Xinjiang Zhongji Red Tomato Industry Co., Ltd., for a period of three years[130]. - The company has engaged a professional institution for asset evaluation related to debt compensation[133]. Social Responsibility and Environmental Impact - The company is recognized as a key agricultural industrialization enterprise and has contributed to local economic development and poverty alleviation efforts in the Xinjiang region[115]. - The company has implemented measures to reduce carbon emissions, focusing on energy conservation and enhancing wastewater treatment capabilities[113]. - The company is committed to fulfilling its social responsibilities and has established a system to regularly evaluate its social responsibility practices[114].